Feb 10, 2022 / 01:30PM GMT
Charles Zhu - Guggenheim Securities, LLC - Analyst
Good morning, everyone, and welcome to day two of our Guggenheim Oncology Conference. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Onconova Therapeutics, a clinical-stage targeted oncology biotech.
Joining us here this morning are several key executives from the company, CEO, Steven Fruchtman; CMO, Mark Gelder; CFO, Mark Guerin; and Avi Oler, SVP of Corporate Development and General Counsel. Guys, thank you very much for your time this morning. Before we break into specific Q&A, could you perhaps provide a two- to three-minute overview of your company pipeline and platform?
Steven Fruchtman - Onconova Therapeutics, Inc. - President & CEO
Charles, thank you so much, and it's a pleasure to speak to the Guggenheim team and investors today. So my name is Dr. Steven Fruchtman, and Charles said I'm the CEO of Onconova. Onconova is a biotech company focusing on patients with refractory cancers.
We have currently two
Onconova Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot